1. Maternal Vascular Malperfusion and Adverse Perinatal Outcomes in Low-Risk Nulliparous Women
- Author
-
Emily Wright, Sarah Keating, Xiang Y. Ye, Stephen J. Lye, Barry Hoffman, Prakesh S. Shah, Melanie C. Audette, and John Kingdom
- Subjects
Adult ,Risk ,medicine.medical_specialty ,Placenta Diseases ,Placenta ,Population ,030204 cardiovascular system & hematology ,Preeclampsia ,03 medical and health sciences ,0302 clinical medicine ,Cost of Illness ,Pre-Eclampsia ,Pregnancy ,medicine ,Humans ,Placental Circulation ,Prospective Studies ,Prospective cohort study ,education ,Disease burden ,education.field_of_study ,030219 obstetrics & reproductive medicine ,Obstetrics ,business.industry ,Incidence ,Incidence (epidemiology) ,Infant, Newborn ,Pregnancy Outcome ,Obstetrics and Gynecology ,medicine.disease ,Parity ,Pregnancy Trimester, Second ,Relative risk ,Infant, Small for Gestational Age ,Small for gestational age ,Female ,business - Abstract
Objective To evaluate the disease burden of placental maternal vascular malperfusion pathology in a low-risk nulliparous population and test the hypothesis that a multiparameter model in the second trimester can predict maternal vascular malperfusion with high precision. Methods A single-center, prospective cohort study was conducted in healthy nulliparous women. Maternal vascular malperfusion disease burden was estimated by incidence, relative risk (RR), and population-attributable risk percent. Maternal risk factors, serum biomarkers, Doppler, and placental morphologic ultrasonography were examined in isolation and in combination for prediction of this placental pathology. Results The incidence of maternal vascular malperfusion pathology was 8.4% (72/856). Women with pathology had higher risk of preeclampsia (8.33% compared with 1.79%; RR 4.67, 95% CI 1.85-11.77%; population-attributable risk 23.6%, 95% CI 16.9-31.6%), small for gestational age (SGA) (47.22% compared with 9.45%; RR 5.00, 95% CI 3.6-6.93%; population-attributable risk 25.2%, 95% CI 22.1-28.5%), and the composite of adverse outcomes (defined as SGA or preeclampsia) (47.22% compared with 10.59%; RR 4.46, 95% CI 3.25-6.13; population-attributable risk 22.5%, 95% CI 19.8-25.5%). The combination of parameters was superior to individual modalities alone in predicting maternal vascular malperfusion, but achieved only moderate precision (area under the curve 0.77, 95% CI 0.71-0.84). Conclusion One in 12 healthy nulliparous women develop maternal vascular malperfusion placental pathology, and these pregnancies had a 4.5 times higher risk of developing preeclampsia or delivering a SGA neonate compared with those without this pathology. A multiparameter model achieved modest precision to predict placental maternal vascular malperfusion. Importantly, in low-risk pregnancies, maternal vascular malperfusion accounts for one fourth of pregnancy outcomes with SGA or preeclampsia. The low population-attributable risk of this placental pathology for SGA and preeclampsia illustrates the importance of discovering novel associations to reduce the disease burden of these pregnancy complications.
- Published
- 2017